Radiopharm Theranostics Ltd (RAD)

Currency in AUD
0.01
0.00(0.00%)
Closed·
Unusual trading volume
Trading near 52-week Low
RAD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.010.01
52 wk Range
0.010.04
Key Statistics
Bid/Ask
0.01 / 0.01
Prev. Close
0.01
Open
0.01
Day's Range
0.01-0.01
52 wk Range
0.01-0.04
Volume
8.5M
Average Volume (3m)
3.39M
1-Year Change
-54.5455%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RAD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.15
Upside
+1,382.65%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.15
(+1,382.65% Upside)

Earnings

Latest Release
Jun 03, 2026
EPS / Forecast
-0.01 / -0.01
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

RAD Income Statement

Compare RAD to Peers and Sector

Metrics to compare
RAD
Peers
Sector
Relationship
P/E Ratio
−1.2x−6.5x−0.3x
PEG Ratio
−0.02−0.030.00
Price/Book
1.1x2.6x2.6x
Price / LTM Sales
3.4x13.1x2.9x
Upside (Analyst Target)
-128.6%56.7%
Fair Value Upside
Unlock17.8%10.2%Unlock

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Employees
14
Market
Australia

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
1.12B31.71%15.73M
Public Companies & Retail Investors
2.42B68.29%33.89M
Total
3.54B100.00%49.62M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Lantheus Holdings, Inc.15.18%537,958,5137,531
Regal Partners Limited9.05%320,694,6804,490

FAQ

What Is the Radiopharm Theranostics (RAD) Stock Price Today?

The Radiopharm Theranostics stock price today is 0.01 AUD.

What Stock Exchange Does Radiopharm Theranostics Trade On?

Radiopharm Theranostics is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Radiopharm Theranostics?

The stock symbol for Radiopharm Theranostics is "RAD."

What Is the Radiopharm Theranostics Market Cap?

As of today, Radiopharm Theranostics market cap is 55.00M AUD.

What Is Radiopharm Theranostics's Earnings Per Share (TTM)?

The Radiopharm Theranostics EPS (TTM) is -0.02.

When Is the Next Radiopharm Theranostics Earnings Date?

Radiopharm Theranostics will release its next earnings report on Sep 24, 2026.

From a Technical Analysis Perspective, Is RAD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Radiopharm Theranostics Stock Split?

Radiopharm Theranostics has split 0 times.

How Many Employees Does Radiopharm Theranostics Have?

Radiopharm Theranostics has 14 employees.

What is the current trading status of Radiopharm Theranostics (RAD)?

As of Jul 30, 2026, Radiopharm Theranostics (RAD) is trading at a price of 0.01 AUD, with a previous close of 0.01 AUD. The stock has fluctuated within a day range of 0.01 AUD to 0.01 AUD, while its 52-week range spans from 0.01 AUD to 0.04 AUD.

What Is Radiopharm Theranostics (RAD) Price Target According to Analysts?

The average 12-month price target for Radiopharm Theranostics is 0.15 AUD, with a high estimate of 0.14826544 AUD and a low estimate of 0.14826544 AUD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,382.65% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.